A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension

Status:

UNKNOWN

A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension

Lead Sponsor:

National Taiwan University Hospital

Conditions:

Hypertension

Eligibility:

All Genders

18-70 years

Phase:

PHASE4

Brief Summary

Objective: * To evaluate the antihypertensive efficacy of two brands of nifedipine 30mg in patients with hypertension. * To assess the safety of 8 weeks of therapy with two brands of nifedipine 30mg ...

Detailed Description

1\. Introduction: Nifedipine is one of the first calcium-channel blockers that are widely used in the treatment of hypertension. Because of its long-term application experience and safety profile, tr...

Eligibility Criteria

Inclusion

Male or non-pregnant female patients aged 18-70 years.
Patients had hypertension with sitting systolic blood pressure 140-180 mmHg, or diastolic blood pressure 90-110 mmHg.
Patients must give written informed consent to participate in this study.

Exclusion

Women who are pregnant or nursing.
Patients have the evidence of secondary or malignant hypertension, history of severe heart disease, cerebrovascular accident within one year, or myocardial infarction within six months.
Patients receiving more than one anti-hypertensive agents or one antihypertensive agent with maximal recommended dosage before entrance into the trial.
Patients with uncontrolled diabetes mellitus.
Patients had known hypersensitivity or contraindication to nifedipine, other calcium channel blockers or other beta-adrenergic antagonists.
Patients have the evidences of hepatic dysfunction (AST, ALT\> 3 times upper limit of normal value), renal dysfunction (serum creatinine concentration\>1.5 mg/dl), pulmonary dysfunction, mental disorders or other concurrent severe disease.
As to the study of flow-mediated dilatation and oxidative stress, patients with diabetes mellitus, dyslipidemia, body mass index \>27, and smokers will be excluded.

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00173667

Last Update

December 21 2005

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)